TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02492490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SVFderived MSC transplantations
Description: infusion of autologous SVF derived MSC to the recipients of DCD kidney transplant.~Subjects with uremia in the intervention group will undergo puncture to collect SVF, then SVF will be cultured to abstain MSC, and the abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD. And the induction therapy of control group will be Basiliximab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basiliximab
Description: induction with Basiliximab before kidney transplantation and on POD 4
Study: NCT04500522

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INH
Description: 3 vaginal tablet of isonicotinic acid hydrazide 900 mg inserted by the patient 12 hours before the scheduled office hysteroscopy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 vaginal tablet of Placebo inserted by the patient 12 hours before the scheduled office hysteroscopy.
Study: NCT05376046

Intervention type: BIOLOGICAL
Intervention: Erythrocytic parameters and thrombin generation assay measurement
Description: Erythrocytic parameters and thrombin generation assay measurement

Intervention type: BIOLOGICAL
Intervention: Erythrocytic parameters and thrombin generation assay measurement
Description: Erythrocytic parameters and thrombin generation assay measurement
Study: NCT04646174

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol adapted for smoking cessation
Description: Treatment components are cognitive-behavioral strategies adapted from the Unified Protocol (UP) for the Transdiagnostic Treatment of Emotional Disorders. Behavioral counseling strategies for smoking cessation, drawn from current US Public Health Service guidelines, are incorporated in each treatment module.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: American Lung Association self-management strategies for smoking cessation
Description: Treatment components are self-management strategies provided through printed self-help materials from the American Lung Association. The materials consist of the Freedom from Smoking guide, Relaxation Exercises for Better Breathing, and COPD; Exercise and Daily Activity guide that address evidence-based smoking cessation and self-management strategies to aid in a quit attempt.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: American Lung Association self-management strategies for smoking cessation
Description: Treatment components are self-management strategies provided through printed self-help materials from the American Lung Association. The materials consist of the Freedom from Smoking guide, Relaxation Exercises for Better Breathing, and COPD; Exercise and Daily Activity guide that address evidence-based smoking cessation and self-management strategies to aid in a quit attempt.
Study: NCT03462940

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholic acid
Description: Tauroursodeoxycholic acid is an ambiphilic bile acid. It is the taurine conjugate form of ursodeoxycholic acid.
Study: NCT02583620

Intervention type: GENETIC
Group type: OTHER
Intervention: blood sample
Description: A blood test is realized on the subject

Intervention type: GENETIC
Group type: OTHER
Intervention: blood sample
Description: A blood test is realized on the subject
Study: NCT01295762

Intervention type: OTHER
Group type: OTHER
Intervention: Immunological analyses
Description: Immunological analyses will be done on blood, bone marrow and tumor samples, at diagnosis, and during the treatment of children diagnosed for neuroblastoma (up to 3 time points). These types of samples are routinely done during conventional neuroblastoma treatment.
Study: NCT04290936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemlidy® (Tenofovir Alafenamide; TAF)
Description: Dosage form: Oral Tablets; Dosage: 25mg; Frequency: One tablet with meals, once daily(QD).
Study: NCT00698906

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine
Description: 5 different formulations, 2-dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine
Description: 5 different formulations, 2-dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine
Description: 5 different formulations, 2-dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine
Description: 5 different formulations, 2-dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV-MPL vaccine
Description: 5 different formulations, 2-dose intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix™-B
Description: 3-dose intramuscular injection
Study: NCT02398877

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stress

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stress

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stress

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stress
Study: NCT02520557

Intervention type: OTHER
Intervention: Blood or Saliva
Description: To screen for HLA genotypes that may place patients at high risk of SCAR when they use ESL.

Intervention type: OTHER
Intervention: Blood or Saliva
Description: To screen for HLA genotypes that may place patients at high risk of SCAR when they use ESL.
Study: NCT02715947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: During The first week: 7.5mg per week, oral; The second and third weeks: 10mg per week, oral; The fourth and fifth weeks: 12.5mg per week,oral; The sixth week:15mg per week, and maintain this dose, oral.
Study: NCT01788956

Intervention type: DEVICE
Intervention: Mespere Venous Oximeter
Description: Mespere Venous oximeter provides non-invasive measurement of the oxygenation of the venous blood.

Intervention type: DEVICE
Intervention: Co-Oximeter
Study: NCT01325207

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be administered twice per week for 4 weeks, then once per week for 4 weeks, and then every 2 weeks
Study: NCT03338361

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: active approach avoidance training and sham visual probe training
Description: patients receive active AAT training and sham VPT training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sham approach avoidance training and active visual probe training
Description: patients receive sham AAT training and active VPT training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: active approach avoidance training and active visual probe training
Description: patients receive active AAT training and active VPT training

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: sham approach avoidance training and sham visual probe training
Description: patients receive sham AAT training and sham VPT training
Study: NCT04330937

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: dietetics
Description: 90 days of consumption

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietetics
Description: 90 days of consumption
Study: NCT04108325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY-20394
Description: Each treatment cycle is comprised of 28-day consecutive of YY-20394, 80mg QD (days 1 to 28). Upon completion of each cycle, patients may continue to receive oral YY-20394 tablets if there are benefit from the treatment and the toxicity is tolerable.
Study: NCT01691248

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fidaxomicin
Description: Fidaxomicin 200 mg tablet once daily from the start (+/- 2 days) of condition (prior to transplantation) or at the time of Fluoroquinolone initiation. Study drug treatment will continue until 7 days after either neutrophil engraftment or the completion of any Fluoroquinolone antibiotic regimen (whichever occurs later).~Study drug treatment will stop at onset of CDAD or no longer than 40 days of duration, even if other antibiotics are still administered or neutrophil engraftment extends beyond 40 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once daily from the start (+/- 2 days) of condition (prior to transplantation) or at the time of Fluoroquinolone initiation. Treatment will continue until 7 days after either neutrophil engraftment or the completion of any Fluoroquinolone antibiotic regimen (whichever occurs later).~Treatment will stop at onset of CDAD or no longer than 40 days of duration, even if other antibiotics are still administered or neutrophil engraftment extends beyond 40 days.
Study: NCT02194309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan low

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan high

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlodipine
Study: NCT00455052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XMT-1001
Description: XMT-1001 is administered as an IV infusion once every 21 days. This expansion of the Phase 1 study is to confirm the MTD.
Study: NCT01003132

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy
Description: Up to 10 sessions of a psychological therapy called Acceptance and Commitment Therapy
Study: NCT01586247

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic
Description: 8g/day galacto-oligosaccharide + 10\^9 CFU/day B.lactis

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 8g/day maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: 8g/day galacto-oligosaccharide

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: 10\^9 CFU/day B.lactis
Study: NCT00927147

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: BNCT
Description: Boronophenylalanine infusion followed by neutron irradiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: cetuximab infusion 250 to 400 mg/kg intravenously, 1 to 3 infusions
Study: NCT05132309

Intervention type: COMBINATION_PRODUCT
Intervention: enzyme replacement therapy
Description: Correction of the previously prescribed dose of enzyme replacement therapy (ERT)/first time selection of ERT according to the severity of pancreatic exocrine insufficiency

Intervention type: COMBINATION_PRODUCT
Intervention: enzyme replacement therapy
Description: Correction of the previously prescribed dose of enzyme replacement therapy (ERT)/first time selection of ERT according to the severity of pancreatic exocrine insufficiency

Intervention type: COMBINATION_PRODUCT
Intervention: enzyme replacement therapy
Description: Correction of the previously prescribed dose of enzyme replacement therapy (ERT)/first time selection of ERT according to the severity of pancreatic exocrine insufficiency

Intervention type: COMBINATION_PRODUCT
Intervention: enzyme replacement therapy
Description: Correction of the previously prescribed dose of enzyme replacement therapy (ERT)/first time selection of ERT according to the severity of pancreatic exocrine insufficiency
Study: NCT03746353

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: early ileostomy closure
Description: Assigned interventions Conventional closure of ileostomy: Surgical closure of the protective ileostomy 90 or more days after the proctectomy surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: early ileostomy closure
Description: Assigned interventions Conventional closure of ileostomy: Surgical closure of the protective ileostomy 90 or more days after the proctectomy surgery
Study: NCT01890915

Intervention type: OTHER
Intervention: Heat Exposure
Description: Heat exposure of 95 degrees F for up to 2 hours.

Intervention type: OTHER
Intervention: Heat Exposure
Description: Heat exposure of 95 degrees F for up to 2 hours.
Study: NCT01759290

Intervention type: DEVICE
Intervention: Absorb Bioresorbable Vascular Scaffold
Description: Subjects receiving the Absorb Bioresorbable Vascular Scaffold
Study: NCT03810430

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: health promotion
Description: health promotion on water, sanitation and hygiene and child feeding along with hygiene kits were delivered to the mothers in the intervention arm
Study: NCT03680963

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-invasive strategy
Description: No indwelling arterial catheter insertion will be allowed during the first 28 days, excepted if predefined safety criteria (indicating absolute need of indwelling arterial catheter insertion) are reached.~In the non-invasive group, automated oscillometric monitor will be used to monitor BP (blood pressure).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control strategy
Description: An indwelling arterial catheter will be inserted as soon as possible (within the first four hours after randomization) and will be maintained except in case of indwelling arterial catheter futility, suspected or proven indwelling arterial catheter related infection or thrombosis (at discretion of attending physician) until day 28 or ICU (Intensive Care Unit) discharge (whichever comes first). After day 28, clinicians may choose to maintain or to remove indwelling arterial catheter.
Study: NCT00966225

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LIP-01
Description: comparison of different dosages of natural health product
Study: NCT03495661

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decompression
Description: Central decompression of the stenotic segment(s) with undercutting of the lateral recesses.
Study: NCT00966225

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LIP-01
Description: comparison of different dosages of natural health product

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LIP-01
Description: comparison of different dosages of natural health product
Study: NCT00674180

Intervention type: BEHAVIORAL
Intervention: Workbook
Description: The workbook developed as a do-it-yourself program in which participants completed self-help sheets that guided them to sections of the workbook most salient to their needs.

Intervention type: BEHAVIORAL
Intervention: Workbook
Description: The workbook developed as a do-it-yourself program in which participants completed self-help sheets that guided them to sections of the workbook most salient to their needs.

Intervention type: BEHAVIORAL
Intervention: Workbook
Description: The workbook developed as a do-it-yourself program in which participants completed self-help sheets that guided them to sections of the workbook most salient to their needs.

Intervention type: BEHAVIORAL
Intervention: Computer Intervention
Description: The computer intervention was provided using a network system that included a file server plus 5 multimedia computers with touch screens. The expert software program was written to guide participants in using the workbook and tail behavioral goals based on their prior computer use and the answers they provided on baseline questionnaires. The three primary paths in the computer addressed nutrition, fitness, and psychobehavioral content.

Intervention type: BEHAVIORAL
Intervention: Computer Intervention
Description: The computer intervention was provided using a network system that included a file server plus 5 multimedia computers with touch screens. The expert software program was written to guide participants in using the workbook and tail behavioral goals based on their prior computer use and the answers they provided on baseline questionnaires. The three primary paths in the computer addressed nutrition, fitness, and psychobehavioral content.

Intervention type: BEHAVIORAL
Intervention: Staff Consultation
Description: The staff consultation component included 6 closed-group workshop sessions and up to 18 telephone or face-to-face consultations with a registered dietician and/or a cognitive behavioral therapist. The workshop curriculum focused on specific activities and assignments in the workbook, and it encouraged use of the computer to identify problems and issues.
Study: NCT03150251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal - oats
Description: Consumption of one cereal in the beginning of each visit

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cereal - cream of rice
Description: Consumption of one cereal in the beginning of each visit

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cereal - cream of rice
Description: Consumption of one cereal in the beginning of each visit
Study: NCT00408902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tandutinib
Description: Given orally, 500 mg bid daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02053532

Intervention type: PROCEDURE
Intervention: Positron emission tomography/magnetic resonance imaging
Description: Positron emission tomography/magnetic resonance (PET/MR) imaging using 18-F-fluorodeoxyglucose (FDG) as radio tracer
Study: NCT00682305

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hematopoietic stem cell transplantation
Description: conditioning regimen:~* day -7: 12g/m\^2 Treosulfan~* day -6: 12g/m\^2 Treosulfan~* day -5: 12g/m\^2 Treosulfan~* day -4: 30mg/kg BW Etoposide~* day -3: 20mg/kg ATG Fresenius (OPTIONAL), 60mg/kg BW Cyclophosphamide~* day -2: 20mg/kg ATG Fresenius (OPTIONAL), 60mg/kg BW Cyclophosphamide~* day -1: 20mg/kg ATG Fresenius (OPTIONAL)~* day 0: SCT
Study: NCT05629949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1701
Description: 8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin®
Description: 8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles.
Study: NCT04290936

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vemlidy® (Tenofovir Alafenamide; TAF)
Description: Dosage form: Oral Tablets; Dosage: 25mg; Frequency: One tablet with meals, once daily(QD).
Study: NCT05629949

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: The recommended dose is 75mg/m2 and the infusion time is approximately 70min (±20min) (or adjusted according to clinical experience at each study center). The drug was administered once every 3 weeks for a treatment cycle of 3 weeks, with the exception of the second day of the first cycle, followed by the first day of each cycle for at least 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: The recommended dose is 75mg/m2 and the infusion time is approximately 70min (±20min) (or adjusted according to clinical experience at each study center). The drug was administered once every 3 weeks for a treatment cycle of 3 weeks, with the exception of the second day of the first cycle, followed by the first day of each cycle for at least 8 cycles
Study: NCT03934073

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DEXTRAIN
Description: 12 sessions of 1 hour of rehabilitation (3 sessions / 4 weeks) for the DexTrain group will consist of 20 minutes of conventional training followed by 40 minutes of exercises using the DexTrain targeting the dexterity components.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONVENTIONNELLE
Description: 12 sessions of 1 hour of rehabilitation (3 sessions / 4 weeks) Conventional will be constituted of conventional training consisting of stretching of the spastic muscles as well as exercises used classically in the protocols of rehabilitation post-stroke

Intervention type: OTHER
Group type: OTHER
Intervention: CONTROLE
Description: Only one assessment will be provided for the control group which will include, Box \& Blocks Test (BBT), FFM Dexterity Assessment, Moberg Pick-Up Test (MPUT), Maximal Finger Tapping Rate, Proprioception, SMT, fMRI, Spontaneous hand activity (accelerometry / portable electromyography)
Study: NCT02946385

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal ABCWY Vaccine
Description: Intramuscular injection of one booster dose at Day 1 to follow-on subjects in the ABCWY_ 0_2 Group, ABCWY_ 0_2_6 Group and ABCWY_ 0_6 Group, primed with 2 or 3 doses of the study vaccine and 2 doses at Days 1 and 61 to naïve subjects in the ABCWY naïve group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ABCWY Vaccine
Description: Intramuscular injection of one booster dose at Day 1 to follow-on subjects in the ABCWY_ 0_2 Group, ABCWY_ 0_2_6 Group and ABCWY_ 0_6 Group, primed with 2 or 3 doses of the study vaccine and 2 doses at Days 1 and 61 to naïve subjects in the ABCWY naïve group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ABCWY Vaccine
Description: Intramuscular injection of one booster dose at Day 1 to follow-on subjects in the ABCWY_ 0_2 Group, ABCWY_ 0_2_6 Group and ABCWY_ 0_6 Group, primed with 2 or 3 doses of the study vaccine and 2 doses at Days 1 and 61 to naïve subjects in the ABCWY naïve group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ABCWY Vaccine
Description: Intramuscular injection of one booster dose at Day 1 to follow-on subjects in the ABCWY_ 0_2 Group, ABCWY_ 0_2_6 Group and ABCWY_ 0_6 Group, primed with 2 or 3 doses of the study vaccine and 2 doses at Days 1 and 61 to naïve subjects in the ABCWY naïve group.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal B Recombinant vaccine
Description: Intramuscular injection of one booster dose of the rMenB+OMV vaccine to subjects in the B_0_2 group, primed with 2 doses of the vaccine and intramuscular injection of 2 doses at Days 1 and 61 in the deltoid area of the non-dominant arm to naïve subjects in the rMenB+OMV Naïve group.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal B Recombinant vaccine
Description: Intramuscular injection of one booster dose of the rMenB+OMV vaccine to subjects in the B_0_2 group, primed with 2 doses of the vaccine and intramuscular injection of 2 doses at Days 1 and 61 in the deltoid area of the non-dominant arm to naïve subjects in the rMenB+OMV Naïve group.
Study: NCT04332978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate
Study: NCT04290936

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage form: Oral Tablets; Dosage: N/A; Frequency: One tablet with meals, once daily(QD).
Study: NCT03356782

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sarcoma-specific CAR-T cells
Description: 1 infusion, for 1x10\^6\~1x10\^7 cells/kg via IV